Pristinamycin is used as an orally active streptogramin-like antibiotic for the treatment of infections caused by multidrug-resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), and vancomycin-resistant Enterococcus faecalis (VREF); it exhibits potent in vitro activity against Staphylococci and Streptococci, including erythromycin-highly-resistant strains, at concentrations ≤0.78 mg/L; in vivo studies demonstrate its efficacy in treating Chlamydia psittaci infection in mice, with significant protection observed at a therapeutic dose of 100 mg/kg.